A Japanese pharmaceutical company focused on developing and commercializing innovative drugs, particularly in infectious diseases and central nervous system disorders. Investors monitor Shionogi for its pipeline of antiviral treatments and historic success with HIV and antibiotic therapies.
5 members of Congress have disclosed 13 trades in Shionogi & Co., Ltd. (SGIOY), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 6 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2024-07-19 | Josh Gottheimer | buy | $1K – $15K |
| 2024-06-18 | Josh Gottheimer | sell | $1K – $15K |
| 2023-10-16 | Josh Gottheimer | buy | $1K – $15K |
| 2023-09-15 | Josh Gottheimer | sell | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $1K – $15K |
| 2023-02-27 | Daniel Goldman | sell | $1K – $15K |
| 2021-04-14 | Josh Gottheimer | buy | $1K – $15K |
| 2021-02-17 | Peter Meijer | sell | $1K – $15K |
| 2020-08-04 | Greg Gianforte | buy | $15K – $50K |
| 2020-02-20 | Greg Gianforte | buy | $100K – $250K |
| 2020-02-18 | Josh Gottheimer | buy | $1K – $15K |
| 2020-02-14 | Josh Gottheimer | buy | $1K – $15K |
| 2018-12-12 | JAMES B. RENACCI | sell | $15K – $50K |